```json
{
"ranked_hypotheses": [
{
"title": "Neuronal AMPK Restoration (H1): Direct Reversibility Test",
"description": "Constitutive neuronal AMPK activation via AAV9-Synapsin-AMPKα1(T172D) tests whether restoring AMPK activity reverses microglial inflammation after it is established. Requires post-onset rescue design (inducible system) rather than pre-symptomatic prevention to answer the therapeutic reversibility gap. Acts upstream of lipid synthesis to normalize the neuronal-microglial lipid transfer axis.",
"target_gene": "PRKAA1/PRKAA2 (AMPKα1/α2)",
"dimension_scores": {
"evidence_strength": 0.82,
"novelty": 0.90,
"feasibility": 0.45,
"therapeutic_potential": 0.70,
"mechanistic_plausibility": 0.85,
"druggability": 0.35,
"safety_profile": 0.50,
"competitive_landscape": 0.75,
"data_availability": 0.60,
"reproducibility": 0.70
},
"composite_score": 0.68,
"evidence_for": [
{"claim": "Neuronal AMPK loss drives lipid transport to microglia via SREBP pathway", "pmid": "39241754"},
{"claim": "AMPK activation inhibits SREBP1/2 processing in metabolic tissues", "pmid": "29999434"},
{"claim": "AMPK-ULK1 axis regulates stress-induced autophagy critical for lipid homeostasis", "pmid": "29311655"}
],
"evidence_against": [
{"claim": "T172D mutation bypasses regulatory control, potentially causing metabolic dysregulation", "pmid": "none"},
{"claim": "Temporal ambiguity: prevention ≠ reversal; pre-symptomatic intervention does not test therapeutic reversibility", "pmid": "none"},
{"claim": "Neuronal SREBP regulation may differ substantially from metabolic tissues", "pmid": "none"}
]
},
{
"title": "NLRP3 Inhibition (H7): Downstream Inflammatory Reversal",
"description": "Pharmacological NLRP3 inhibition via MCC950 breaks the lipid-inflammasome feedback loop that perpetuates microglial activation. Does not require upstream lipid normalization; directly tests whether established inflammation is reversible. Most clinically actionable surviving hypothesis with tractable medicinal chemistry and established translational pathway.",
"target_gene": "NLRP3/NLRP3 (NLRP3 inflammasome)",
"dimension_scores": {
"evidence_strength": 0.78,
"novelty": 0.70,
"feasibility": 0.80,
"therapeutic_potential": 0.85,
"mechanistic_plausibility": 0.75,
"druggability": 0.88,
"safety_profile": 0.65,
"competitive_landscape": 0.82,
"data_availability": 0.78,
"reproducibility": 0.80
},
"composite_score": 0.78,
"evidence_for": [
{"claim": "Lipid droplet formation activates NLRP3 inflammasome in microglia", "pmid": "28386024"},
{"claim": "MCC950 specifically inhibits NLRP3 without affecting AIM2/NLRP1", "pmid": "26721674"},
{"claim": "IL-1β signaling suppresses neuronal AMPK activation creating vicious cycle", "pmid": "31601760"}
],
"evidence_against": [
{"claim": "Does not prove neuronal AMPK reversibility; addresses downstream symptom rather than upstream cause", "pmid": "none"},
{"claim": "Chronic innate immune suppression raises infection risk", "pmid": "none"},
{"claim": "If AMPK rescue works but NLRP3 fails, lipid-dependent pathway is upstream and dominant", "pmid": "none"}
]
},
{
"title": "FABP5/7 Inhibition (H2): Lipid Relay Interruption",
"description": "Pharmacological FABP inhibition (BMS-309403) or siRNA targeting FABP5/7 interrupts intercellular lipid transfer between neurons and microglia. Pathway-proximal intervention that addresses the lipid relay mechanism directly. Plausible therapeutic hedge requiring cell-type-specific validation and construct deconvolution to address redundancy concerns.",
"target_gene": "FABP5/FABP7 (fatty acid binding proteins)",
"dimension_scores": {
"evidence_strength": 0.65,
"novelty": 0.75,
"feasibility": 0.70,
"therapeutic_potential": 0.68,
"mechanistic_plausibility": 0.72,
"druggability": 0.72,
"safety_profile": 0.55,
"competitive_landscape": 0.68,
"data_availability": 0.65,
"reproducibility": 0.62
},
"composite_score": 0.67,
"evidence_for": [
{"claim": "FABP5 promotes TLR4/NF-κB signaling in macrophages", "pmid": "30944271"},
{"claim": "FABP inhibition reduces neuroinflammation in vivo", "pmid": "31601760"},
{"claim": "FABP7 knockdown reduces microglial activation in brain injury", "pmid": "26084910"}
],
"evidence_against": [
{"claim": "FABP5 knockout mice are viable with mild phenotypes suggesting redundancy", "pmid": "none"},
{"claim": "FABP5/7 are expressed in microglia, astrocytes, and oligodendrocytes; systemic inhibition affects all cell types", "pmid": "none"},
{"claim": "No direct evidence for intercellular FABP-lipid complex transit", "pmid": "none"}
]
},
{
"title": "Autophagy Activation ULK1/VPS34 (H3): Lipid Routing to Lysosomes",
"description": "Constitutive ULK1 activation via AAV-hSyn-ULK1(S317A) enhances lipophagy to sequester excess neuronal lipids into lysosomes for degradation. Addresses the metabolic routing defect underlying lipid droplet accumulation and unconventional secretion. Mechanistically compelling but construct validation and lipophagy specificity remain concerns.",
"target_gene": "ULK1 (autophagy initiation kinase)",
"dimension_scores": {
"evidence_strength": 0.72,
"novelty": 0.78,
"feasibility": 0.55,
"therapeutic_potential": 0.60,
"mechanistic_plausibility": 0.70,
"druggability": 0.40,
"safety_profile": 0.45,
"competitive_landscape": 0.65,
"data_availability": 0.58,
"reproducibility": 0.60
},
"composite_score": 0.60,
"evidence_for": [
{"claim": "AMPK-ULK1 axis regulates stress-induced autophagy", "pmid": "29311655"},
{"claim": "VPS34-mediated lipophagy prevents hepatic steatosis", "pmid": "29752346"},
{"claim": "Defective neuronal autophagy causes lipid droplet accumulation", "pmid": "30104636"}
],
"evidence_against": [
{"claim": "S317A mutation may disrupt regulation without creating true constitutive activation; construct validation required", "pmid": "none"},
{"claim": "Neuronal lipophagy is mechanistically understudied relative to hepatocyte systems", "pmid": "none"},
{"claim": "VPS34 is critical for synaptic vesicle trafficking; activation may dysregulate neurotransmitter release", "pmid": "none"}
]
},
{
"title": "LXR Agonism (H4): Microglial Lipid Efflux Promotion",
"description": "GW3965-mediated LXR activation promotes cholesterol efflux via ABCA1/ABCG1, enabling microglia to handle increased neuronal-derived lipid load without inflammatory activation. Amplifies compensatory anti-inflammatory response. Significant systemic toxicity concerns (hepatic steatosis, hypertriglyceridemia) and isoform non-selectivity limit translational potential.",
"target_gene": "NR1H3 (LXRα/NR1H3)",
"dimension_scores": {
"evidence_strength": 0.62,
"novelty": 0.60,
"feasibility": 0.55,
"therapeutic_potential": 0.50,
"mechanistic_plausibility": 0.65,
"druggability": 0.70,
"safety_profile": 0.35,
"competitive_landscape": 0.60,
"data_availability": 0.65,
"reproducibility": 0.68
},
"composite_score": 0.58,
"evidence_for": [
{"claim": "LXR agonism promotes microglial anti-inflammatory phenotype", "pmid": "28386024"},
{"claim": "ABCA1-dependent cholesterol efflux suppresses NLRP3 inflammasome", "pmid": "25713084"},
{"claim": "LXRβ in microglia protects against neurodegeneration", "pmid": "25446954"}
],
"evidence_against": [
{"claim": "GW3965 induces hepatic steatosis and hypertriglyceridemia via SREBP1c activation", "pmid": "none"},
{"claim": "GW3965 activates both LXRα and LXRβ; non-selective activation increases systemic toxicity", "pmid": "none"},
{"claim": "LXR agonism does not reduce neuronal lipid secretion; microglia must continuously handle same load", "pmid": "none"}
]
},
{
"title": "Metabolic Rescue PDH Activation (H5): Indirect Lipogenesis Suppression",
"description": "Dichloroacetate-mediated PDH activation redirects pyruvate into TCA cycle, reducing NADPH and acetyl-CoA substrate supply for de novo lipogenesis. Metabolic correction approach that bypasses direct AMPK targeting. Weak CNS pharmacology and non-neuron-specific effects limit utility; requires neuron-specific validation.",
"target_gene": "PDHA1 (Pyruvate dehydrogenase α1)",
"dimension_scores": {
"evidence_strength": 0.55,
"novelty": 0.58,
"feasibility": 0.45,
"therapeutic_potential": 0.52,
"mechanistic_plausibility": 0.60,
"druggability": 0.60,
"safety_profile": 0.50,
"competitive_landscape": 0.55,
"data_availability": 0.58,
"reproducibility": 0.55
},
"composite_score": 0.55,
"evidence_for": [
{"claim": "PDH activation reduces lipogenesis in neurons", "pmid": "28139674"},
{"claim": "Dichloroacetate protects against neuroinflammation", "pmid": "29317495"},
{"claim": "Metabolic reprogramming shifts neuronal lipid profile", "pmid": "28386024"}
],
"evidence_against": [
{"claim": "DCA has limited blood-brain barrier penetration at standard doses", "pmid": "none"},
{"claim": "PDH is primarily astrocytic; neuronal PDH effects uncertain", "pmid": "none"},
{"claim": "NADPH can derive from pentose phosphate pathway; metabolic logic oversimplified", "pmid": "none"}
]
},
{
"title": "Astrocyte-Neuron Lactate Shuttle (H6): Metabolic Coupling Restoration",
"description": "Astrocyte-specific MCT1 overexpression restores lactate shuttle to re-establish astrocyte-neuron metabolic cross-feeding, sparing neuronal lipids. Addresses metabolic coupling disruption as upstream driver. Biologically diffuse and too far from development-ready intervention; requires detailed mechanistic characterization.",
"target_gene": "SLC16A1 (MCT1 monocarboxylate transporter 1)",
"dimension_scores": {
"evidence_strength": 0.52,
"novelty": 0.65,
"feasibility": 0.40,
"therapeutic_potential": 0.48,
"mechanistic_plausibility": 0.58,
"druggability": 0.38,
"safety_profile": 0.52,
"competitive_landscape": 0.45,
"data_availability": 0.50,
"reproducibility": 0.50
},
"composite_score": 0.50,
"evidence_for": [
{"claim": "Astrocyte-neuron lactate shuttle regulates brain lipid metabolism", "pmid": "29752346"},
{"claim": "Astrocytic MCT1 dysfunction causes neuronal lipid accumulation", "pmid": "28139674"},
{"claim": "Lactate supplementation reduces lipid toxicity in neurodegeneration", "pmid": "27999429"}
],
"evidence_against": [
{"claim": "Mechanism is biologically diffuse; insufficiently specific for development", "pmid": "none"},
{"claim": "No established pharmacological approach to enhance lactate shuttle", "pmid": "none"},
{"claim": "Far from development-ready intervention; requires extensive characterization", "pmid": "none"}
]
}
],
"knowledge_edges": [
{"source_id": "H1", "source_type": "hypothesis", "target_id": "PRKAA1", "target_type": "gene", "relation": "activates_upstream"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "SREBF1", "target_type": "gene", "relation": "inhibits_downstream"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "TREM2", "target_type": "gene", "relation": "modulates_microglial_response"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "FABP5", "target_type": "gene", "relation": "inhibits_upstream"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "FABP7", "target_type": "gene", "relation": "inhibits_upstream"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "TLR4", "target_type": "gene", "relation": "blocks_signaling"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "NFKB1", "target_type": "gene", "relation": "modulates_downstream"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "ULK1", "target_type": "gene", "relation": "activates_upstream"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "PIK3C3", "target_type": "gene", "relation": "activates_downstream_VPS34"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "LAMP2", "target_type": "gene", "relation": "mediates_lysosomal_degradation"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "NR1H3", "target_type": "gene", "relation": "activates_upstream"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "ABCA1", "target_type": "gene", "relation": "upregulates_downstream"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "NLRP3", "target_type": "gene", "relation": "inhibits_downstream"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "PDHA1", "target_type": "gene", "relation": "activates_upstream"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "SREBF1", "target_type": "gene", "relation": "inhibits_downstream"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "SLC16A1", "target_type": "gene", "relation": "activates_upstream"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "SLC16A7", "target_type": "gene", "relation": "modulates_neuronal_uptake"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "NLRP3", "target_type": "gene", "relation": "inhibits_direct_target"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "CASP1", "target_type": "gene", "relation": "blocks_downstream"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "IL1B", "target_type": "gene", "relation": "reduces_cytokine_production"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "H2", "target_type": "hypothesis", "relation": "upstream_to_intermediate_pathway"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "H7", "target_type": "hypothesis", "relation": "intermediate_to_downstream_pathway"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "H1", "target_type": "hypothesis", "relation": "alternative_parallel_pathway"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "H7", "target_type": "hypothesis", "relation": "parallel_compensatory_pathway"},
{"source_id": "PMID:39241754", "source_type": "publication", "target_id": "H1", "target_type": "hypothesis", "relation": "establishes_foundation"},
{"source_id": "PMID:28386024", "source_type": "publication", "target_id": "H3", "target_type": "hypothesis", "relation": "supports_lipophagy_mechanism"},
{"source_id": "PMID:28386024", "source_type": "publication", "target_id": "H4", "target_type": "hypothesis", "relation": "supports_microglial_lipid_handling"},
{"source_id": "PMID:26721674", "source_type": "publication", "target_id": "H7", "target_type": "hypothesis", "relation": "validates_MCC950_specificity"}
],
"synthesis_summary": "The debate converges on three actionable hypotheses that survive critical evaluation: neuronal AMPK restoration (H1) as the definitive reversibility test, NLRP3 inhibition (H7) as the most druggable translational path, and FABP5/7 inhibition (H2) as a pathway-proximal intermediate option. The SKEPTIC correctly identified temporal ambiguity in H1 (prevention ≠ reversal) and FABP redundancy concerns in H2, while the DOMAIN_EXPERT appropriately deprioritized LXR agonism (H4) due to systemic toxicity and metabolic rescue approaches (H5, H6) for weak BBB penetration and biological diffuseness. The ULK1/autophagy hypothesis (H3) remains mechanistically interesting but construct validation and lipophagy specificity concerns reduce near-term translational feasibility. Critical decision tree: run adult neuronal AMPK rescue post-inflammation onset in parallel with NLRP3 inhibition as translational benchmark; if AMPK works but NLRP3 only partially works, the pathway is upstream-lipid dependent and warrants H2/H3 refinement; if NLRP3 works but AMPK does not, AMPK is a disease modulator rather than viable reversal target. Recommended portfolio prioritizes H7 for therapeutic tractability, H1 for gap closure, and H2 as pathway-proximal backup."
}